{"id":"W3030729340","doi":"10.1200/jco.2020.38.15_suppl.6010","title":"A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Institutes of Health; Conquer Cancer Foundation","keywords":"Medicine; Nivolumab; Internal medicine; Clinical endpoint; Oncology; Cabozantinib; Progression-free survival; Endometrial cancer; Urology; Cancer; Surgery; Gastroenterology; Immunotherapy; Randomized controlled trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002735337,0.0001403199,0.001701916,0.00008195215,0.00003384809,0.000005450652,0.0002137189,0.0002685279,0.0000524725],"category_scores_gemma":[0.005364385,0.0001086534,0.0004454555,0.0001806666,0.0002085912,0.000006865958,0.0001579765,0.0003292213,4.603118e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002570751,"about_ca_system_score_gemma":0.0008162346,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001090465,"about_ca_topic_score_gemma":0.0002580177,"domain_scores_codex":[0.9963021,0.0008478071,0.002175648,0.0002638205,0.0002204953,0.0001901799],"domain_scores_gemma":[0.9970164,0.0007662039,0.0016229,0.0001238001,0.0002441667,0.000226555],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8209942,0.004579257,0.004817476,0.00002069925,0.0009115909,0.00006403013,0.0004119058,0.00004326862,0.003325805,0.00001497395,0.00247013,0.1623467],"study_design_scores_gemma":[0.8644792,0.09235495,0.001110165,0.00003017469,0.0003988606,0.000009725909,0.0005091734,0.0001520421,0.0009618781,0.00001060763,0.03982986,0.000153302],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907607,0.005991298,0.00006676296,0.001064086,0.001552721,0.0003644407,0.0000112152,0.000001608533,0.0001871709],"genre_scores_gemma":[0.991659,0.006193344,0.000236199,0.0002838952,0.001577746,0.0000138178,0.000002397842,0.000012451,0.00002111293],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1621934,"threshold_uncertainty_score":0.6422058,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1661395798558401,"score_gpt":0.4908497602442609,"score_spread":0.3247101803884208,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}